Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:01:38.848Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:01:38.848Z.
Quote observation: 2026-10-06T15:00:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a667a199b47e7e336467208d2f6772290b800d1a0ab6507ee3a182ebbb9f075
FORWARD PE RATIO
N/A
BGM Group Ltd.
Market Cap
$108.60M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BGM Group Ltd. (BGM) | $108.60M | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.57M | N/A |
| Immunic, Inc. (IMUX)vs › | $108.29M | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.27M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $108.98M | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.07M | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $110.05M | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.08M | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.00M | 5.11 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.73M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
